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Introduction
The quest for important medical knowledge – the kind that
clarifies understanding of or that leads to successful
interventions for important clinical problems – has always
required departure from accepted norms of medical practice.
Innovation in medicine (i.e. trying out new or revised clinical
practices to improve health outcomes for individual patients)
remains a central feature of medical practice and varies from
minor adjustments to ‘radical new procedures’ [1]. It is doubtful
that any thoughtful physician or surgeon has not at some time
tailored a patient’s treatment to fit specific circumstances, or
adjusted a standard dose of a medication in an attempt to
maximize the patient’s benefit. When Thomas Percival [2]
suggested, in 1803, that some of these departures from
accepted practice were sufficiently bold to warrant seeking the
opinion of medical colleagues before conducting them in
patients, he ushered in the age of peer review in medicine.
As recently as the early 1960s, peer review in research was
viewed by many investigators and research administrators with
the same suspicion that Percival undoubtedly encountered in
the 1800s. However, in the wake of the thalidomide tragedy of
the late 1950s and early 1960s, revelations in 1963 of
researchers injecting elderly indigent patients with live cancer
cells at the Brooklyn Jewish Chronic Diseases Hospital, and in
the same year an ethically dubious and unsuccessful
chimpanzee to human kidney transplant at Tulane University
[3], the specter of lost public trust in the research enterprise
forced two critical issues onto the agenda. First, how should
the risks associated with medical research be dealt with, and,
Commentary
Monitoring and oversight in critical care research
James V Lavery1, Marleen LP Van Laethem2 and Arthur S Slutsky3
1Research Scientist, Centre for Global Health Research and Inner City Health Research Unit, St. Michael’s Hospital, and Assistant Professor,
Department of Public Health Sciences and Joint Centre for Bioethics, University of Toronto, Toronto, Canada
2Research Ethics Monitor, St. Michael’s Hospital, Toronto, Canada
3Vice President, Research, St. Michael’s Hospital, and Division Director, Interdepartmental Division of Critical Care Medicine, Professor of Medicine,
Surgery and Biomedical Engineering, University of Toronto, Toronto, Canada
Correspondence: James V Lavery, laveryj@smh.toronto.on.ca
Published online: 28 September 2004 Critical Care 2004, 8:403-405 (DOI 10.1186/cc2964)
This article is online at http://ccforum.com/content/8/6/403
© 2004 BioMed Central Ltd
Abstract
Institutionally based research ethics review is a form of peer review that has – for better or worse –
become the norm throughout the world. The vast majority of research ethics review takes the form of
protocol review alone, conducted in advance of the research. Although oversight and monitoring in
clinical research have long been recognized as essential features of sound research ethics, they are
seldom exercised in ways that fulfill their motivating goals: to ensure that research is conducted as
planned; that research participants comprehend the information presented to them in the consent
process; and that the potential benefits and risks of study participation remain acceptable. Annual
review of continuing research, monitoring informed consent, monitoring adherence to approved
protocols and monitoring integrity of research data comprise the main types of monitoring and
oversight activity. We believe that our institutionally based systems of research ethics review and
responsibility require greater engagement and participation from researchers and research
administrators. The appropriate role of critical care researchers and research administrators is to
provide leadership to move toward a greater recognition of the importance of monitoring and oversight
for ethical and high quality clinical research.
Keywords critical care research, institutional accountability, institutional review boards, oversight and monitoring
of research, research ethics, research ethics board, research ethics review, research integrity404
Critical Care    December 2004 Vol 8 No 6 Lavery et al.
second, how should the burgeoning research enterprise be
governed [4]? In 1965, the US National Institutes of Health
(NIH) director Dr James Shannon championed a policy
whereby the NIH would fund research in human subjects only
if, ‘the judgment of the investigator is subject to prior review by
his [sic] institutional associates’ [5]. This policy formalized the
practice of institutionally based research ethics review, a form
of ethics peer review that has – for better or worse – become
the norm throughout the world.
The vast majority of research ethics review takes the form of
protocol review alone, conducted in advance of the research.
The goal of these reviews is to determine the ethical
acceptability of the proposed research. When this has been
done, authorization may be given to the investigators to
proceed with their proposed research. Investigators are
required to conduct the research according to the approved
protocol and to give regular status reports (at least annually)
in order for approval to be extended. However, research
ethics scandals have shown that the limited scope of
research ethics review can provide sufficient opportunity for
those few investigators who choose to take shortcuts,
proceed carelessly, and even occasionally engage in willfully
unethical conduct to avoid the scrutiny of their peers. Such
deviations from the approved protocol can have grave
consequences, both in terms of the safety of research
participants and in public trust in the research enterprise.
Challenges in oversight and monitoring
The lack of effective oversight and monitoring in clinical
research makes it similar in many respects to clinical practice,
especially that by independent, individual physicians. The
similar levels of latitude and independence of action raise the
question of whether oversight of clinical research may be
sufficiently served, post hoc, through litigation by injured
parties – a familiar mode of oversight in clinical practice [1].
Since Shannon’s institution of peer review at the NIH, the
process of ethics approval for research studies by institutional
research ethics boards (REBs; also known as institutional
review boards or research ethics committees), including formal
informed consent procedures as well as annual status reports,
have been widely accepted as a sufficient institutional
response to ethical challenges in research. According to
McDonald [6], ‘(t)he REB process (and with it the focus on the
research proposal and the consent form) has become the
reification of the sum total of responsibilities and
accountabilities for researchers, research institutions, research
sponsors, and research regulators. In effect, this rationalizes
the avoidance of major responsibilities that arise before, after
and on the peripheries of the REB review process.’
The current state of oversight and monitoring of clinical
research make them the Achilles’ Heel of research ethics, the
flaw that fatally weakens the rest of the operation. Although
these practices have long been recognized as essential
features of sound research ethics, they are seldom exercised in
ways that fulfill their motivating goals, which are ‘to ensure that
research is conducted as planned, that research subjects
comprehend the information presented to them in the consent
process, and that the potential benefits and risks of study
participation remain acceptable’ [7]. In part, this reflects the
fact that, despite important improvement in awareness and
interest in research ethics within the research community, the
review and oversight of research are still viewed by many
investigators as an intrusion on their professional discretion
and as obstacles to research, rather than integral and complex
challenges for enhancing research conduct and governance.
As such, research ethics review, oversight and monitoring
remain among the small handful of essential research related
activities that are conducted on an almost entirely voluntary
basis. Institutions either lack the resources or the motivation (or
both) to ensure that these activities occur and are done well.
Oversight and monitoring practices
Research monitoring and oversight encompass four types of
activity [8]: annual review of continuing research, monitoring
of informed consent, monitoring of adherence to approved
protocols and monitoring the integrity of data. These
activities are intended as means of quality assurance in
research, and as means of establishing expectations of
rigorous and ethical conduct in research. However, there are
very few empirical research data to demonstrate how well
these practices fulfill these functions [9,10], and the few
epidemiological studies of monitoring and continuing review
suggest much room for improvement [8]. Furthermore, it is
also taken on faith that when these activities do occur they
contribute to the higher order aims of protecting human
participants and promoting ethical conduct in research, but
similar deficits in empirical evidence make these claims
increasingly suspect and raise a deeper question about what
we are trying to achieve through research ethics review,
monitoring and oversight practices, and how.
According to the Canadian Tri-Council Policy Statement:
Ethical Conduct for Research Involving Humans [11],
‘(p)rinciples of accountability require that, regardless of the
review strategy, the REB continue to be responsible for the
ethics of all research involving human subjects that is carried
out within the institution.’ In interviews with REB members at
several major Canadian universities, however, McDonald [6]
found them to be apprehensive about monitoring. This seems
a reasonable response to the ambiguous message of the Tri-
Council Policy Statement, which, in a subsequent section,
states that ‘(b)eyond scrutinizing reports, the REB itself
should not normally carry out the continuing ethics review,
except in specific cases where the REB believes that it is
best suited to intervene’ [11]. So, the committees most
responsible for research ethics continue to be given few, if
any, resources and little helpful guidance on these matters.
Our own hospital, St. Michael’s Hospital, has taken the
unusual step of implementing a monitoring programme with a405
full-time research ethics monitor. Through judicious use of
skill, diplomacy and diligence, and with strong support from
the hospital’s research administration, we are forging what
we believe is a fruitful new direction in research monitoring
and oversight. We are working to create a climate and
culture within the institution that support investigators with
the myriad technical requirements of research, particularly the
Canadian and US regulatory requirements for clinical trials,
but also to provide them with meaningful opportunities to
discuss and examine the complex ethical and regulatory
issues that arise in the conduct of their research.
Our monitoring programme places strong emphasis on
education. We provide investigators with detailed information
about research responsibilities through regularly scheduled
rounds and a variety of other educational activities, such as
courses in the International Conference on Harmonisation’s
Good Clinical Practice guidelines [12]. We conduct internal
quality assurance audits of ongoing trials, initiated either by
random selection, investigator request, or in response to
specific events or concerns. We have also monitored
informed consent discussions between research staff and
prospective research participants, and we are currently
planning to survey research participants themselves in order
to gain a better understanding of their perspective.
These activities not only engage investigators with the issues,
but they also provide the REB with a real and meaningful set of
mechanisms to help it fulfill its obligations for monitoring and
oversight. The REB members receive feedback about the actual
conduct of the research that they approved, and this constitutes
an important learning loop for their review of future proposals.
The institution is also exercising due diligence by gathering
more details about the conduct of its research, especially for
investigator-initiated drug studies, in which the institution must
assume sponsor responsibilities. Our researchers have
responded very favourably to acknowledgement and support for
the high standards of their conduct, and to recommendations
for improvement, when these are warranted.
Conclusion
Given the many ethical challenges inherent in critical care
research, it would be tempting to propose a separate and
distinct approach to their monitoring and oversight. We do not
see it that way. Although perplexing challenges related to
monitoring and oversight in critical care research will invariably
arise [13–15], such as informed consent from a substitute
decision maker for those patients whose capacity changes
over time [16,17], similar challenges are equally likely to arise
in other clinical research fields. We believe that our
institutionally based system of research ethics review and
responsibility requires greater engagement and participation
of researchers and research administrators so that they can
help to compensate for the limitations of the ethics review
process, rather than ignoring or taking advantage of them. We
need better professional ownership of these issues by
investigators and clinical departments, and institutional pride
in affording these issues the time, resources and intellectual
commitment that they deserve. The appropriate role for critical
care researchers and administrators in this respect is to help
provide the necessary leadership to move beyond the limits of
current research ethics review practices and toward a greater
recognition of the importance of monitoring and oversight for
the performance of ethical and high quality clinical research.
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